• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例罕见的帕博利珠单抗相关的格雷夫斯病病例。

A Rare Case of Pembrolizumab-Associated Graves' Disease.

作者信息

Alqaisi Sura, Rahman Ali

机构信息

Internal Medicine, Memorial Healthcare, Pembroke Pines, USA.

Internal Medicine, Northwell Health at Mather Hospital, Port Jefferson, USA.

出版信息

Cureus. 2023 Feb 6;15(2):e34696. doi: 10.7759/cureus.34696. eCollection 2023 Feb.

DOI:10.7759/cureus.34696
PMID:36909047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9998112/
Abstract

Immune checkpoint inhibitors (ICPis), such as pembrolizumab (Keytruda®), are associated with the development of several immune-related adverse events (irAEs). Thyroid dysfunction is a common endocrine irAE associated with pembrolizumab; however, Graves' disease induced by pembrolizumab is extremely rare. Few cases of this condition have been reported in the literature. Here, we report the case of a 50-year-old patient who presented with thyrotoxicosis that was attributed to Graves' disease secondary to pembrolizumab therapy.

摘要

免疫检查点抑制剂（ICPis），如帕博利珠单抗（可瑞达®），与多种免疫相关不良事件（irAEs）的发生有关。甲状腺功能障碍是与帕博利珠单抗相关的常见内分泌irAE；然而，帕博利珠单抗诱发的格雷夫斯病极为罕见。文献中报道的此类病例很少。在此，我们报告一例50岁患者，其出现甲状腺毒症，归因于帕博利珠单抗治疗继发的格雷夫斯病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c20a/9998112/a7e647aefd0d/cureus-0015-00000034696-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c20a/9998112/28820876a56b/cureus-0015-00000034696-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c20a/9998112/a7e647aefd0d/cureus-0015-00000034696-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c20a/9998112/28820876a56b/cureus-0015-00000034696-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c20a/9998112/a7e647aefd0d/cureus-0015-00000034696-i02.jpg

相似文献

1
A Rare Case of Pembrolizumab-Associated Graves' Disease.一例罕见的帕博利珠单抗相关的格雷夫斯病病例。
Cureus. 2023 Feb 6;15(2):e34696. doi: 10.7759/cureus.34696. eCollection 2023 Feb.
2
Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.免疫检查点抑制剂诱发的格雷夫斯病：一例报告及文献复习
Eur Thyroid J. 2019 Jul;8(4):192-195. doi: 10.1159/000501824. Epub 2019 Jul 9.
3
Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review).免疫检查点抑制剂治疗期间的格雷夫斯病（病例系列及文献综述）
Cancers (Basel). 2021 Apr 17;13(8):1944. doi: 10.3390/cancers13081944.
4
Atezolizumab-Induced Hypothyroidism in a Patient With Pre-existing Triiodothyronine (T3) Thyrotoxicosis Due to Graves' Disease: A Case Report and Literature Review.一例因格雷夫斯病导致已有三碘甲状腺原氨酸（T3）甲状腺毒症的患者发生阿替利珠单抗诱导的甲状腺功能减退：病例报告及文献综述
Cureus. 2021 Nov 19;13(11):e19736. doi: 10.7759/cureus.19736. eCollection 2021 Nov.
5
New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report.纳武利尤单抗治疗胃癌后新发格雷夫斯病：病例报告。
BMC Endocr Disord. 2020 Aug 26;20(1):132. doi: 10.1186/s12902-020-00613-5.
6
Immune checkpoint inhibitor-related thyroid dysfunction.免疫检查点抑制剂相关的甲状腺功能障碍。
Best Pract Res Clin Endocrinol Metab. 2022 May;36(3):101660. doi: 10.1016/j.beem.2022.101660. Epub 2022 Apr 12.
7
Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.免疫检查点抑制剂联合化疗导致的涉及甲状腺的迟发性免疫相关不良事件：一例报告及回顾性队列研究
Endocr J. 2023 Mar 28;70(3):323-332. doi: 10.1507/endocrj.EJ22-0467. Epub 2022 Dec 2.
8
A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient.一例抗人程序性细胞死亡蛋白1单克隆抗体帕博利珠单抗诱发膀胱癌患者格雷夫斯病的病例报告
Case Rep Endocrinol. 2019 Oct 17;2019:2314032. doi: 10.1155/2019/2314032. eCollection 2019.
9
Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?格雷夫斯病患者使用免疫检查点抑制剂治疗后出现甲状腺功能减退：治愈？
JCEM Case Rep. 2022 Dec 3;1(1):luac024. doi: 10.1210/jcemcr/luac024. eCollection 2023 Jan.
10
Graves' disease with only unilateral involvement; a case report.仅单侧受累的格雷夫斯病；病例报告。
Int J Surg Case Rep. 2024 Jan;114:109138. doi: 10.1016/j.ijscr.2023.109138. Epub 2023 Dec 9.

引用本文的文献

1
Challenges in subtyping disease entities of thyroid dysfunction following combined immune checkpoint inhibitor therapy: a case report.联合免疫检查点抑制剂治疗后甲状腺功能障碍疾病实体亚型分类的挑战：一例报告
Thyroid Res. 2025 Jul 15;18(1):35. doi: 10.1186/s13044-025-00254-7.

本文引用的文献

1
New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.一名转移性肺癌患者使用帕博利珠单抗后新发自身免疫性糖尿病和甲状腺功能减退症。
Endocrinol Diabetes Metab Case Rep. 2022 Feb 1;2022. doi: 10.1530/EDM-21-0123.
2
Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review).免疫检查点抑制剂治疗期间的格雷夫斯病（病例系列及文献综述）
Cancers (Basel). 2021 Apr 17;13(8):1944. doi: 10.3390/cancers13081944.
3
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma.
FDA 批准概要：帕博利珠单抗用于 MSI-H/dMMR 不可切除或转移性结直肠癌一线治疗。
Clin Cancer Res. 2021 Sep 1;27(17):4680-4684. doi: 10.1158/1078-0432.CCR-21-0557. Epub 2021 Apr 12.
4
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.PD-1/PD-L1 抑制剂癌症治疗的研究现状与展望。
Drug Des Devel Ther. 2020 Sep 8;14:3625-3649. doi: 10.2147/DDDT.S267433. eCollection 2020.
5
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.根据美国国立综合癌症网络（NCCN）指南及证据水平对美国食品药品监督管理局（FDA）批准的免疫检查点抑制剂适应症的综述。
Cancers (Basel). 2020 Mar 20;12(3):738. doi: 10.3390/cancers12030738.
6
A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient.一例抗人程序性细胞死亡蛋白1单克隆抗体帕博利珠单抗诱发膀胱癌患者格雷夫斯病的病例报告
Case Rep Endocrinol. 2019 Oct 17;2019:2314032. doi: 10.1155/2019/2314032. eCollection 2019.
7
Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.免疫检查点抑制剂诱发的格雷夫斯病：一例报告及文献复习
Eur Thyroid J. 2019 Jul;8(4):192-195. doi: 10.1159/000501824. Epub 2019 Jul 9.
8
Immune checkpoint inhibitors: recent progress and potential biomarkers.免疫检查点抑制剂：最新进展与潜在生物标志物。
Exp Mol Med. 2018 Dec 13;50(12):1-11. doi: 10.1038/s12276-018-0191-1.
9
A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.一例与帕博利珠单抗（可瑞达）治疗相关的格雷夫斯眼病病例。
J AAPOS. 2018 Aug;22(4):310-312. doi: 10.1016/j.jaapos.2018.01.006. Epub 2018 Apr 4.
10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.接受免疫检查点抑制剂治疗患者免疫相关不良事件的管理：美国临床肿瘤学会临床实践指南摘要
J Oncol Pract. 2018 Apr;14(4):247-249. doi: 10.1200/JOP.18.00005. Epub 2018 Mar 8.